LivaNova PLC (NASDAQ:LIVN) Short Interest Update

LivaNova PLC (NASDAQ:LIVN) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 2,436,767 shares, a growth of 32.7% from the January 15th total of 1,836,041 shares. Based on an average daily volume of 603,535 shares, the days-to-cover ratio is currently 4.0 days. Currently, 4.5% of the company’s stock are short sold. Currently, 4.5% of the company’s stock are short sold. Based on an average daily volume of 603,535 shares, the days-to-cover ratio is currently 4.0 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LIVN shares. Barclays increased their target price on shares of LivaNova from $58.00 to $67.00 and gave the stock an “equal weight” rating in a report on Friday, January 9th. Stifel Nicolaus raised their price objective on shares of LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Mizuho increased their price target on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. KeyCorp began coverage on LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $69.38.

Institutional Trading of LivaNova

A number of large investors have recently modified their holdings of the company. UMB Bank n.a. grew its position in shares of LivaNova by 22.6% in the 4th quarter. UMB Bank n.a. now owns 971 shares of the company’s stock worth $60,000 after buying an additional 179 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of LivaNova by 1.7% during the 3rd quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock valued at $845,000 after purchasing an additional 274 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of LivaNova by 28.8% in the 4th quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock worth $78,000 after purchasing an additional 283 shares in the last quarter. Finally, Bayforest Capital Ltd grew its stake in LivaNova by 44.8% during the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after buying an additional 284 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Up 1.8%

LIVN opened at $66.96 on Wednesday. The stock has a 50-day moving average of $63.78 and a 200 day moving average of $57.95. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. LivaNova has a 12 month low of $32.48 and a 12 month high of $67.92. The firm has a market cap of $3.66 billion, a P/E ratio of -16.74 and a beta of 0.97.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.